Virus-Immunotherapy combo takes on tough cancers
NCT ID NCT03647163
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 26 times
Summary
This study tests a new combination treatment for people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The treatment uses a modified virus (VSV-IFNβ-NIS) plus an immunotherapy drug (pembrolizumab) to help the immune system fight cancer. The goal is to find the best dose and see if the combination can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.